A Phase I Study of MK-4827 in Combination With Temozolomide in Patients With Advanced Cancer.
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2014
At a glance
- Drugs Niraparib; Temozolomide
- Indications Cancer; Glioblastoma; Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 04 Sep 2012 New source identified and integrated (M.D. Anderson Cancer Center; 2010-0856).
- 04 Sep 2012 Planned number of patients changed from 54 to 64 as reported by M.D. Anderson Cancer Center.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History